Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

Clinical trial NCT05096715 · RECRUITING

Trial details

NCT number: NCT05096715
Sponsor: Massachusetts General Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Unresectable Hepatocellular Carcinoma

Start date: 2022-08-23
Primary completion: 2027-01-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.